ENOVIS CORP (ENOV) Stock Fundamental Analysis

NYSE:ENOV • US1940141062

22.88 USD
+0.46 (+2.05%)
At close: Feb 24, 2026
22.88 USD
0 (0%)
After Hours: 2/24/2026, 7:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, ENOV scores 4 out of 10 in our fundamental rating. ENOV was compared to 185 industry peers in the Health Care Equipment & Supplies industry. While ENOV is still in line with the averages on profitability rating, there are concerns on its financial health. ENOV may be a bit undervalued, certainly considering the very reasonable score on growth


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year ENOV was profitable.
  • ENOV had a positive operating cash flow in the past year.
  • In multiple years ENOV reported negative net income over the last 5 years.
  • Of the past 5 years ENOV 4 years had a positive operating cash flow.
ENOV Yearly Net Income VS EBIT VS OCF VS FCFENOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M -800M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -30.84%, ENOV is in line with its industry, outperforming 42.70% of the companies in the same industry.
  • The Return On Equity of ENOV (-67.66%) is comparable to the rest of the industry.
  • Looking at the Return On Invested Capital, with a value of 0.12%, ENOV is in the better half of the industry, outperforming 64.32% of the companies in the same industry.
Industry RankSector Rank
ROA -30.84%
ROE -67.66%
ROIC 0.12%
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ENOV Yearly ROA, ROE, ROICENOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30

1.3 Margins

  • ENOV's Operating Margin of 0.25% is fine compared to the rest of the industry. ENOV outperforms 64.32% of its industry peers.
  • In the last couple of years the Operating Margin of ENOV has declined.
  • ENOV's Gross Margin of 57.19% is in line compared to the rest of the industry. ENOV outperforms 57.84% of its industry peers.
  • ENOV's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 0.25%
PM (TTM) N/A
GM 57.19%
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
ENOV Yearly Profit, Operating, Gross MarginsENOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • ENOV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for ENOV has been increased compared to 1 year ago.
  • Compared to 5 years ago, ENOV has more shares outstanding
  • The debt/assets ratio for ENOV is higher compared to a year ago.
ENOV Yearly Shares OutstandingENOV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ENOV Yearly Total Debt VS Total AssetsENOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

  • ENOV has an Altman-Z score of 0.72. This is a bad value and indicates that ENOV is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.72, ENOV is in line with its industry, outperforming 49.19% of the companies in the same industry.
  • The Debt to FCF ratio of ENOV is 59.72, which is on the high side as it means it would take ENOV, 59.72 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 59.72, ENOV is doing good in the industry, outperforming 67.03% of the companies in the same industry.
  • ENOV has a Debt/Equity ratio of 0.66. This is a neutral value indicating ENOV is somewhat dependend on debt financing.
  • The Debt to Equity ratio of ENOV (0.66) is worse than 65.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 59.72
Altman-Z 0.72
ROIC/WACC0.01
WACC9.58%
ENOV Yearly LT Debt VS Equity VS FCFENOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

2.3 Liquidity

  • ENOV has a Current Ratio of 2.22. This indicates that ENOV is financially healthy and has no problem in meeting its short term obligations.
  • ENOV has a Current ratio of 2.22. This is comparable to the rest of the industry: ENOV outperforms 43.24% of its industry peers.
  • A Quick Ratio of 1.16 indicates that ENOV should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.16, ENOV is doing worse than 70.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.22
Quick Ratio 1.16
ENOV Yearly Current Assets VS Current LiabilitesENOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 26.14% over the past year.
  • The earnings per share for ENOV have been decreasing by -16.18% on average. This is quite bad
  • ENOV shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.57%.
  • ENOV shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.73% yearly.
EPS 1Y (TTM)26.14%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%2.74%
Revenue 1Y (TTM)11.57%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%8.65%

3.2 Future

  • The Earnings Per Share is expected to grow by 23.19% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 8.87% on average over the next years. This is quite good.
EPS Next Y14.9%
EPS Next 2Y11.19%
EPS Next 3Y11.64%
EPS Next 5Y23.19%
Revenue Next Year7.32%
Revenue Next 2Y6%
Revenue Next 3Y6.02%
Revenue Next 5Y8.87%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ENOV Yearly Revenue VS EstimatesENOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1B 2B 3B 4B
ENOV Yearly EPS VS EstimatesENOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 6.87, the valuation of ENOV can be described as very cheap.
  • Based on the Price/Earnings ratio, ENOV is valued cheaper than 98.38% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.98. ENOV is valued rather cheaply when compared to this.
  • With a Price/Forward Earnings ratio of 6.54, the valuation of ENOV can be described as very cheap.
  • 98.38% of the companies in the same industry are more expensive than ENOV, based on the Price/Forward Earnings ratio.
  • ENOV's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.01.
Industry RankSector Rank
PE 6.87
Fwd PE 6.54
ENOV Price Earnings VS Forward Price EarningsENOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • ENOV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ENOV is cheaper than 93.51% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ENOV indicates a somewhat cheap valuation: ENOV is cheaper than 71.89% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 57.48
EV/EBITDA 8.77
ENOV Per share dataENOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.46
PEG (5Y)N/A
EPS Next 2Y11.19%
EPS Next 3Y11.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ENOV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ENOVIS CORP

NYSE:ENOV (2/24/2026, 7:00:00 PM)

After market: 22.88 0 (0%)

22.88

+0.46 (+2.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06
Earnings (Next)02-26
Inst Owners117.36%
Inst Owner Change0.03%
Ins Owners1.14%
Ins Owner Change0.32%
Market Cap1.31B
Revenue(TTM)2.23B
Net Income(TTM)-1.37B
Analysts84.44
Price Target46.36 (102.62%)
Short Float %15.5%
Short Ratio8.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.55%
Min EPS beat(2)7.76%
Max EPS beat(2)13.35%
EPS beat(4)4
Avg EPS beat(4)8.22%
Min EPS beat(4)4.97%
Max EPS beat(4)13.35%
EPS beat(8)8
Avg EPS beat(8)7.21%
EPS beat(12)12
Avg EPS beat(12)8.15%
EPS beat(16)16
Avg EPS beat(16)8.66%
Revenue beat(2)0
Avg Revenue beat(2)-0.15%
Min Revenue beat(2)-0.21%
Max Revenue beat(2)-0.09%
Revenue beat(4)0
Avg Revenue beat(4)-0.8%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)-0.09%
Revenue beat(8)2
Avg Revenue beat(8)-0.81%
Revenue beat(12)4
Avg Revenue beat(12)-0.8%
Revenue beat(16)5
Avg Revenue beat(16)-4.71%
PT rev (1m)0%
PT rev (3m)-9.09%
EPS NQ rev (1m)0.92%
EPS NQ rev (3m)1.06%
EPS NY rev (1m)0.29%
EPS NY rev (3m)2.05%
Revenue NQ rev (1m)-0.14%
Revenue NQ rev (3m)-0.25%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.04%
Valuation
Industry RankSector Rank
PE 6.87
Fwd PE 6.54
P/S 0.59
P/FCF 57.48
P/OCF 6.03
P/B 0.65
P/tB N/A
EV/EBITDA 8.77
EPS(TTM)3.33
EY14.55%
EPS(NY)3.5
Fwd EY15.29%
FCF(TTM)0.4
FCFY1.74%
OCF(TTM)3.8
OCFY16.59%
SpS39.05
BVpS35.33
TBVpS-8.37
PEG (NY)0.46
PEG (5Y)N/A
Graham Number51.45
Profitability
Industry RankSector Rank
ROA -30.84%
ROE -67.66%
ROCE 0.15%
ROIC 0.12%
ROICexc 0.12%
ROICexgc 0.34%
OM 0.25%
PM (TTM) N/A
GM 57.19%
FCFM 1.02%
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-45.54%
ROICexc growth 3YN/A
ROICexc growth 5Y-43.8%
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 59.72
Debt/EBITDA 4.5
Cap/Depr 66.6%
Cap/Sales 8.7%
Interest Coverage 250
Cash Conversion 72.98%
Profit Quality N/A
Current Ratio 2.22
Quick Ratio 1.16
Altman-Z 0.72
F-Score4
WACC9.58%
ROIC/WACC0.01
Cap/Depr(3y)55.91%
Cap/Depr(5y)50.8%
Cap/Sales(3y)7.49%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.14%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%2.74%
EPS Next Y14.9%
EPS Next 2Y11.19%
EPS Next 3Y11.64%
EPS Next 5Y23.19%
Revenue 1Y (TTM)11.57%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%8.65%
Revenue Next Year7.32%
Revenue Next 2Y6%
Revenue Next 3Y6.02%
Revenue Next 5Y8.87%
EBIT growth 1Y-35.24%
EBIT growth 3YN/A
EBIT growth 5Y-48.51%
EBIT Next Year76.65%
EBIT Next 3Y28.13%
EBIT Next 5Y28.11%
FCF growth 1Y122.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y609.06%
OCF growth 3Y-31.69%
OCF growth 5Y-2.82%

ENOVIS CORP / ENOV FAQ

What is the ChartMill fundamental rating of ENOVIS CORP (ENOV) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ENOV.


What is the valuation status of ENOVIS CORP (ENOV) stock?

ChartMill assigns a valuation rating of 8 / 10 to ENOVIS CORP (ENOV). This can be considered as Undervalued.


Can you provide the profitability details for ENOVIS CORP?

ENOVIS CORP (ENOV) has a profitability rating of 4 / 10.


What is the earnings growth outlook for ENOVIS CORP?

The Earnings per Share (EPS) of ENOVIS CORP (ENOV) is expected to grow by 14.9% in the next year.